Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
9.18
+0.05 (0.55%)
Mar 9, 2026, 3:37 PM EDT - Market open
Seres Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.35 | - | - | - | 144.93 | 33.22 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | 336.33% | -3.74% | Upgrade
|
| Cost of Revenue | 14.5 | 14.53 | 19.34 | 13.43 | 141.89 | 90.57 | Upgrade
|
| Gross Profit | -14.15 | -14.53 | -19.34 | -13.43 | 3.04 | -57.36 | Upgrade
|
| Selling, General & Admin | 44.08 | 53.18 | 77.5 | 70.26 | 69.26 | 30.78 | Upgrade
|
| Research & Development | 45.2 | 53.6 | 98.26 | 96.22 | - | - | Upgrade
|
| Other Operating Expenses | - | - | - | - | -1.73 | - | Upgrade
|
| Operating Expenses | 89.28 | 106.79 | 175.76 | 166.49 | 67.53 | 30.78 | Upgrade
|
| Operating Income | -103.43 | -121.32 | -195.1 | -179.91 | -64.49 | -88.13 | Upgrade
|
| Interest Expense | - | - | -2.47 | -6.02 | -2.91 | -2.92 | Upgrade
|
| Interest & Investment Income | 2.22 | 3.97 | 7.3 | 3.06 | 2.87 | 0.95 | Upgrade
|
| Other Non Operating Income (Expenses) | 44.73 | 9.29 | -0.1 | -0.02 | -0.55 | 1.43 | Upgrade
|
| EBT Excluding Unusual Items | -56.48 | -108.06 | -190.37 | -182.89 | -65.08 | -88.68 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.24 | -0.69 | -0.5 | -0.45 | Upgrade
|
| Gain (Loss) on Sale of Assets | 85.27 | 5.68 | - | - | - | - | Upgrade
|
| Other Unusual Items | -23.4 | -23.4 | - | - | - | - | Upgrade
|
| Pretax Income | 5.39 | -125.77 | -190.13 | -183.58 | -65.58 | -89.13 | Upgrade
|
| Earnings From Continuing Operations | 5.39 | -125.77 | -190.13 | -183.58 | -65.58 | -89.13 | Upgrade
|
| Earnings From Discontinued Operations | - | 125.91 | 76.41 | -66.58 | - | - | Upgrade
|
| Net Income | 5.39 | 0.14 | -113.72 | -250.16 | -65.58 | -89.13 | Upgrade
|
| Net Income to Common | 5.39 | 0.14 | -113.72 | -250.16 | -65.58 | -89.13 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 8 | 6 | 5 | 5 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 8 | 6 | 5 | 5 | 4 | Upgrade
|
| Shares Change (YoY) | 19.92% | 21.40% | 18.44% | 17.86% | 14.93% | 40.85% | Upgrade
|
| EPS (Basic) | 0.62 | 0.02 | -17.77 | -46.29 | -14.30 | -22.34 | Upgrade
|
| EPS (Diluted) | 0.62 | 0.02 | -17.77 | -46.29 | -14.30 | -22.34 | Upgrade
|
| Free Cash Flow | -23.37 | -148.99 | -125.33 | -238.64 | -2.88 | -94.2 | Upgrade
|
| Free Cash Flow Per Share | -2.69 | -19.18 | -19.58 | -44.16 | -0.63 | -23.61 | Upgrade
|
| Gross Margin | - | - | - | - | 2.10% | -172.68% | Upgrade
|
| Operating Margin | -29466.95% | - | - | - | -44.50% | -265.33% | Upgrade
|
| Profit Margin | 1536.75% | - | - | - | -45.25% | -268.33% | Upgrade
|
| Free Cash Flow Margin | -6657.55% | - | - | - | -1.99% | -283.61% | Upgrade
|
| EBITDA | -99.17 | -115.85 | -188.85 | -173.29 | -58.55 | -81.55 | Upgrade
|
| EBITDA Margin | - | - | - | - | -40.40% | -245.53% | Upgrade
|
| D&A For EBITDA | 4.26 | 5.47 | 6.24 | 6.63 | 5.95 | 6.58 | Upgrade
|
| EBIT | -103.43 | -121.32 | -195.1 | -179.91 | -64.49 | -88.13 | Upgrade
|
| EBIT Margin | - | - | - | - | -44.50% | -265.33% | Upgrade
|
| Revenue as Reported | 0.35 | - | - | - | 144.93 | 33.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.